The Journal of Infectious Diseases · 1990 · 61 citations · 30 references
Veterinary MedicineImmunologyInfectious DiseasesHost-pathogen InteractionsImmunology Of Infectious DiseasesInnate ImmunityInnate Immune Responses To ParasitesMacrophage BiologyMacrophage Responses To ParasitesParasitic Disease PathogenesisProtozoan Host-parasite InteractionsProtozoan PathogenesisCytokine CombinationsCytokine MediatorsLeishmaniasis PathogenesisMacrophage Activation By ProtozoaMacrophage Responses To LeishmaniaMacrophage-parasite InteractionsTreatment Of LeishmaniasisVisceral Leishmaniasis
Leishmania organisms are important pathogens, causing diseases worldwide. Standard therapies are often toxic and are not always effective. The effect of recombinant human granulocyte-macrophage and macrophage colony-stimulating factors (GM-CSF and M-CSF) on intramacrophage survival of Leishmania mexicana amazonensis (Lma) were compared with those of interferon-gamma (IFN-gamma). Macrophages previously infected with Lma were treated with or without GM-CSF and M-CSF. Compared with no cytokine treatment, treatment with GM-CSF (0.1-100 ng/ml) or M-CSF (1:3.5 X 10(6) - 1:3.5 X 10(3) dilutions) caused a significant dose-dependent reduction in intracellular parasites, 427 +/- 20 (mean +/- SE) Lma/100 macrophages. GM-CSF or M-CSF in combination with IFN-gamma resulted in more effective inhibition of intracellular parasites. Thus, the cytostatic activity appears to require interaction between cytokines, macrophages, and amastigotes. These cytokines are potential therapeutic agents for visceral leishmaniasis.
30